Researchers reported virus-like particles that enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells, a step toward higher-throughput functional genomics in cell types central to immunotherapy. Nature Biotechnology described efficient editing using VLP-based delivery while aiming to reduce toxicity and inflammation challenges that have limited other approaches. The platform supports pooled CRISPR screens, which can map gene dependencies and regulatory factors across large variant sets in relevant immune cells. Because monocytes, macrophages, and dendritic cells respond strongly to foreign nucleic acids, delivery method performance is a recurring bottleneck. If the method scales, it can accelerate target identification for immunotherapies that depend on manipulating myeloid phenotypes, while improving experimental reproducibility compared with less controllable delivery systems.